Hybrid Cell Inventions: Section 3(j) of the Patents Act Does Not Apply

Hybrid Cell Inventions: Section 3(j) of the Patents Act Does Not Apply Featured image for article: Hybrid Cell Inventions: Section 3(j) of the Patents Act Does Not Apply

In a recent decision, the Calcutta High Court upheld an appeal filed by BTS Research International Pty Ltd (“BTS”) challenging the rejection by the Assistant...

Read more about Hybrid Cell Inventions: Section 3(j) of the Patents Act Does Not Apply

Madras High Court Affirms Rejection of AI-Integrated Persona Patent

Madras High Court Affirms Rejection of AI-Integrated Persona Patent Featured image for article: Madras High Court Affirms Rejection of AI-Integrated Persona Patent

The Madras High Court dismissed an appeal challenging the rejection of a patent application for AI-integrated persona augmentation. The Court ruled that the invention lacked sufficient technical detail, inventive step, and patent-eligible subject matter under the Patents Act. It upheld the Controller’s decision, emphasizing the absence of tangible technical effects and clear disclosure requirements.

Read more about Madras High Court Affirms Rejection of AI-Integrated Persona Patent

Methods for Antibody Production in Genetically Modified Animals are Patentable; they are not covered under Section 3(i) Exclusion

The Madras High Court ruled that methods for producing antibodies in genetically modified animals are patentable under Indian law and are not excluded by Section 3(i). This decision clarifies the scope of patent eligibility for biotechnological inventions involving animal models.

Read more about Methods for Antibody Production in Genetically Modified Animals are Patentable; they are not covered under Section 3(i) Exclusion

Monoclonal antibodies and Patents – How the Madras High Court interpreted Section 3(c)

The Madras High Court clarified the interpretation of Section 3c regarding patent eligibility of monoclonal antibodies in India. The Court held that synthetic antibodies may be patentable if they demonstrate novelty or technical advancement.

Read more about Monoclonal antibodies and Patents – How the Madras High Court interpreted Section 3(c)

Engineered non-living substances are not excluded under Section 3(c) of the Patents Act, 1970.

The Madras High Court held that Section 3c of the Patents Act, 1970 does not exclude engineered non-living substances from patent protection. The ruling clarifies the distinction between discovery and invention for biotechnology patents in India.

Read more about Engineered non-living substances are not excluded under Section 3(c) of the Patents Act, 1970.